Chemotherapy-associated steatohepatitis

Annals of Hepatology

Dominique Larrey¹  Lucy Meunier² 

[1] Corresponding author at: Hôpital Saint Eloi, 80 Avenue Fliche, 34295 Montpellier Cedex 5, France.;Service d’Hépato-gastroentérologie et Transplantation, France;

关键词: Chemotherapy-associated steatohepatitis (CASH);    Chemotherapy;    Hepatotoxicity;    Steatosis;    Steatohepatitis;   

DOI  :  

来源: DOAJ

【 摘 要 】

Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as “CASH” for “Chemotherapy-induced Acute Steatohepatitis”. The mechanism of toxicity is essentially based on mitochondrial toxicity. These lesions are chronic and often reversible when the treatment is stopped. Contributing factors related to the patient, the disease or the treatment play a major role in the emergence of CASH. It is important to identify chemotherapies with steatosis or steatohepatitis as risk factors in order to improve control of the metabolic risk factors associated with the patient and to reinforce monitoring during treatment. In the particular context of neo-adjuvant chemotherapy for metastatic colorectal cancer, a short duration of chemotherapy and a few-weeks delay between chemotherapy and surgery could reduce postoperative morbidity and mortality.

【 授权许可】

Unknown